Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-S…

SAN DIEGO--(Business Wire/Korea Newswire)--Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncology ...